
Torrent Pharma launches oral and injectable formulations of Semaglutide
New Delhi: Torrent Pharmaceuticals today announced the launch of its Semaglutide brands – Sembolic and Semalix – in India, in both oral and injectable formulations. The launch expands the company’s presence in metabolic disorders such as type-2 diabetes and obesity. Commenting on the launch, Amal Kelshikar, CEO – India Business, Torrent Pharma, said: “Metabolic disorders represent one of the most significant healthcare challenges in India with a significant portion of our population affected by Type-2 Diabetes. Our entry into the GLP-1 therapy segment reflects Torrent’s commitment to expanding treatment options











































